BioMarin to acquire Amicus Therapeutics for $4.8 Billion
Dec 19 (Reuters) - BioMarin Pharmaceutical BMRN.O said on Friday it will acquire Amicus Therapeutics FOLD.O in an all-cash deal worth about $4.8 billion. (Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Amicus Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Amicus Q4 revenue beats estimates